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MaSympathovagal imbalance contributes to progressive worsening of heart failure (HF) and is associated with untoward
clinical outcomes. Based on compelling pre-clinical studies that supported the role of autonomic modulation in HF
models, a series of clinical studies were initiated using spinal cord stimulation, vagus nerve stimulation, and baroreceptor
activation therapy in patients with HF with a reduced ejection fraction. Whereas the phase II studies with baroreceptor
activation therapy remain encouraging, the larger clinical studies with spinal cord stimulation and vagus nerve
stimulation have yielded disappointing results. Here we will focus on the pre-clinical studies that supported the role of
neuromodulation in the failing heart, as well provide a critical review of the recent clinical trials that have sought to
modulate autonomic tone in HF patients. This review will conclude with an analysis of some of the difﬁculties in
translating device-based modulation of the autonomic nervous system from pre-clinical models into successful
clinical trials, as well as provide suggestions for how to move the ﬁeld of neuromodulation forward.
(J Am Coll Cardiol Basic Trans Science 2016;1:95–106) ©2016TheAuthors. PublishedbyElsevier onbehalf of theAmerican
College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).OVERVIEW OF THE CARDIAC
AUTONOMIC NERVOUS SYSTEM
Details of the complex regulation of the autonomic
nervous system (ANS) have been provided in several
recent reviews and will be discussed here only
brieﬂy in order to provide the proper context for the
discussion of the clinical studies of device-based
modulation of ANS (“neuromodulation”) in heart
failure (HF) (1,2). ANS consists of the parasympathetic
nervous system and the sympathetic nervous
system (SNS). Physiologically, these 2 systems are
diametrically opposed, yet work together synergisti-
cally in a reciprocal manner, in order to provide the
cardiovascular system with the ability to respond
quickly to both internal and external stimuli (3).
Both the SNS and the ANS are reﬂex circuits
composed of “motor” (efferent) ﬁbers that convey
information from the central nervous system to them the Center for Cardiovascular Research, Cardiovascular Division, Depar
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and parasympathetic ﬁbers that convey information
from the heart to the central nervous system. The
heart also receives afferent parasympathetic input
from a series of mechanosensitive nerve endings in
large arteries and the carotid sinuses, collectively
referred to as baroreceptors, because they are sensi-
tive to changes in blood pressure and blood volume.
The baroreceptors from the carotid arteries have
axons in the glossopharyngeal nerve, and those from
the aorta have axons that travel in the vagus nerve.
The baroreﬂex is a major homeostatic mechanism for
maintaining blood pressure and is responsible for
controlling the afterload of the heart. Baroreceptors
are activated by the opening of mechanosensitive ion
channels within the sensory terminals, which in turn
activate afferent ﬁbers that terminate in the nucleus
tractus solitarius in the medulla oblongata. Increased
baroreﬂex activity (e.g., in hypertension) results in atment of Medicine, Washington University School of
ips relevant to the contents of this paper to disclose.
ABBR EV I A T I ON S
AND ACRONYMS
ANS = autonomic nervous
system
BAT = baroreceptor activation
therapy
HF = heart failure
HFrEF = heart failure with a
reduced ejection fraction
LV = left ventricular
LVEF = left ventricular ejection
fraction
MSNA = muscle sympathetic
nervous activity
MI = myocardial infarction
NE = norepinephrine
NT-proBNP = N-terminal
pro–B-type natriuretic peptide
NYHA = New York Heart
Association
OMT = optimal medical therapy
SCS = spinal cord stimulation
SNS = sympathetic nervous
system
VF = ventricular ﬁbrillation
VNS = vagus nerve stimulation
VT = ventricular tachycardia
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96reﬂex increase in parasympathetic activity
that triggers a reﬂex inhibition of sympa-
thetic tone, thus restoring autonomic bal-
ance. Conversely, decreased baroreﬂex
activity (e.g., in hypotension) results in
withdrawal of parasympathetic tone that re-
sults in a reﬂex increase in sympathetic tone.
SYMPATHOVAGAL IMBALANCE IN
HEART FAILURE
The clinical syndrome of heart failure with a
reduced ejection fraction (HFrEF) is associ-
ated with sustained activation of the sym-
pathetic nervous system that is accompanied
by a withdrawal of parasympathetic tone
(2,4,5). Although these disturbances in auto-
nomic control were initially attributed to loss
of the inhibitory input from arterial or car-
diopulmonary baroreceptor reﬂexes, there is
increasing evidence that excitatory reﬂexes
may also participate in the autonomic
imbalance that occurs in HF (2). Under
normal conditions, inhibitory inputs from
“high pressure” carotid sinus and aortic arch
baroreceptors and the “low pressure” car-
diopulmonary mechanoreceptors are the
principal inhibitors of sympathetic outﬂow,whereas discharge from the nonbaroreﬂex peripheral
chemoreceptors and muscle “metaboreceptors” are
the major excitatory inputs to sympathetic outﬂow.
The parasympathetic limb of the baroreceptor heart
rate reﬂex is also responsive to arterial baroreceptor
afferent inhibitory input. At rest, healthy individuals
display low sympathetic discharge and high rate
variability. In HF patients, the peripheral baroreﬂex
responses become suppressed (“blunted”) as HF
worsens (6). Blunting of the peripheral arterial and
cardiopulmonary baroreceptors results in a dere-
pression of the sympathetic outﬂow from the central
nervous systems and a net increase in efferent sym-
pathetic nerve activity that is accompanied by
decreased efferent parasympathetic tone. Conse-
quently, patients with HF have a loss of heart rate
variability and increased peripheral vascular resis-
tance (2).
Dysregulation of the ANS in HF has received
considerable attention over the past 3 decades,
because of the well-recognized association between
increased sympathetic activity and “neurohormonal”
activation. Although increased sympathetic stimula-
tion provides short-term support for the cardiovas-
cular system, the sustained activation of the SNS is
maladaptive in the long term because it is directlytoxic to the heart and circulation and also leads to
activation of the renin-angiotensin system, which can
also be deleterious to the heart and circulation
(reviewed in [7]). However, the role of the para-
sympathetic nervous system in the pathophysiology
of HF is less well understood. In isolated organ
preparations, human in vitro data, and in animal
models, local muscarinic receptor stimulation results
in inhibition of norepinephrine (NE) release from
sympathetic nerve terminals (8,9). In vivo, it has been
shown that cardiac NE spillover was greater in pa-
tients with HF than those with normal LV function,
and that infusion with acetylcholine attenuates the
amount of NE release in these patients. This effect
was not seen in the presence of atropine, suggesting
that it is mediated via muscarinic receptor activation
(10,11). The ATRAMI (Autonomic Tone and Reﬂexes
After Myocardial Infarction) trial was the ﬁrst large
multicenter clinical study to examine impairment in
vagal activity as a prognostic marker following
myocardial infarction (MI). ATRAMI enrolled 1,284
post-MI patients and followed them over a 2-year
period and showed that patients with depressed
baroreﬂex sensitivity (a marker of decreased vagal
activity) had decreased survival (5). The depressed
baroreﬂex sensitivity was also shown to be associated
with a worse New York Heart Association (NYHA)
functional class and higher mortality in HF patients.
The prognostic value of the depressed baroreﬂex
sensitivity among patients with HFrEF was also
observed in the presence of beta-blocker therapy
(12,13). These observations have led to the develop-
ment of various device-based therapies that are
designed to restore the sympathovagal imbalance in
patients with HF.
THERAPEUTIC MODULATION OF THE
AUTONOMIC NERVOUS SYSTEM IN
HEART FAILURE
It bears emphasis that many of the current therapies
for HFrEF patients reverse the sympathovagal imbal-
ance that develops in HF, including pharmacologic
therapy with beta-blockers and angiotensin-
converting enzyme inhibitors and angiotensin-
receptor blockers, exercise training, and cardiac
resynchronization therapy (reviewed in [14]). Despite
the tremendous progress in treating patients with
HF, the great majority of patients with HF will
eventually develop worsening HF (15). Thus, there
continues to be an unmet need for new therapies for
treating patients with HF. To this end, there has been
growing interest in directly modulating the ANS
as a means of counteracting the sympathovagal
FIGURE 1 The Autonomic Nervous System
Diagram of pre-ganglionic and post-ganglionic sympathetic and parasympathetic ﬁbers.
Reproduced with permission from Klauber RE. Cardiovascular Pharmacology Concepts:
Autonomic Ganglia. January 27, 2012. Available at: http://cvpharmacology.com/
autonomic_ganglia. Accessed March 10, 2016.
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97imbalance that develops in HF. In the following re-
view, we will focus on the pre-clinical and clinical
studies that have employed spinal cord stimulation
(SCS), vagus nerve stimulation (VNS), and barore-
ceptor activation therapy (BAT) in HF, with the goal
of deconstructing these studies in order to better
understand why it has been so difﬁcult to translate
the encouraging pre-clinical studies into successful
phase II/III clinical trials. The important therapeutic
areas of renal nerve denervation and left cardiac
sympathetic denervation have been the subject of
several recent reviews and will not be discussed
herein (1).
VAGUS NERVE STIMULATION. VNS has been used in
humans and has been approved by the U.S. Food and
Drug Administration for the treatment of epilepsy
(1997) and refractory depression (2005). The device
that is used for the treatment of epilepsy and
depression is composed of a pulse generator, a bipolar
lead that is implanted in the mid-cervical portion of
the left vagus nerve, and delivers a biphasic current
that continuously cycles between on and off periods
to stimulate afferent vagus nerve ﬁbers. Importantly,
2 of 3 VNS devices used in patients with HFrEF were
developed for use in patients with epilepsy and/or
depression.
Pre-c l in i ca l s tud ies of VNS. The salutary role VNS
in the heart was ﬁrst shown by a series of experi-
mental studies by Vanoli et al. (16), who demon-
strated that VNS prevented ventricular ﬁbrillation
(VF) induced by acute myocardial ischemia in the
setting of a healed MI. In animal models of HF, VNS
resulted in increased survival (17), improved ven-
tricular function (17,18), as well as decreased inﬂam-
mation (18). Indeed, the anti-inﬂammatory effects of
VNS following ischemia and reperfusion injury are
accompanied by a reduction in the number of mac-
rophages and apoptotic cells that is paralleled by
decreased levels of circulating pro-inﬂammatory
cytokines (19), which has been referred to as the
“cholinergic anti-inﬂammatory reﬂex” (20).
Cl in ica l s tud ies of VNS. In the clinical setting VNS
is performed by placing an electrode cuff around the
right or left cervical vagus (21,22), thereby stimulating
both the efferent and afferent vagus nerve ﬁbers. It
should be recognized that stimulation of afferent
vagus nerve ﬁbers experimentally can have profound
effects on the activity of the contralateral efferent
parasympathetic tone (increased activity) and
efferent sympathetic tone (inhibition of activity).
However, it is unclear at the time of this writing
whether it is preferable to stimulate afferent of
efferent vagus nerve ﬁbers.Four clinical studies of VNS in humans have been
completed and published thus far (Table 1). The ﬁrst
VNS study in humans was the CardioFit pilot, which
enrolled 32 patients with a history of chronic NYHA
functional class II to IV HF and a left ventricular
ejection fraction (LVEF) <35% (22). The patients were
already receiving optimal medical treatment (OMT)
with beta-blockers, angiotensin-converting enzyme
inhibitors/angiotensin-receptor blockers and loop
diuretics. Additionally, 19 of the 32 patients had an
implantable cardioverter-deﬁbrillator. The CardioFit
(Bio Control Medical, Yehud, Israel) system is a
“closed loop” device system with an intracardiac
right ventricular sensing lead and a bipolar cuff
placed around the right cervical vagus nerve
(Figure 2A). The stimulation intensity of VNS, which
was limited by patient symptoms of hoarseness and/
or referred jaw pain, was uptitrated to 4.1  1.2 mA.
A clear demonstration of efferent vagus nerve stim-
ulation in the CardioFit pilot trial was demonstrated
by the change in resting heart rate during the trial,
which decreased signiﬁcantly during from 82  13
beats/min to 76  13 beats/min during the study. At
6 months w60% of patients improved by at least
1 NYHA functional class (Figure 3) and the Minnesota
TABLE 1 Vagal Nerve Stimulation
Study Design Patient Characteristics N Outcomes Results
CardioFit
(NCT00461019)
Nonrandomized
Open label
NYHA functional
classes II and III
EF <35%
32 1. Occurrence of all system and/or
procedure-related adverse
events (6 months)
2. NYHA functional class, 6MWD,
LVESV, MLHFQ QoL scores
No signiﬁcant adverse events
Signiﬁcant improvement in
NYHA functional class,
6MWD, LVESV, and QoL
scores
NECTAR-HF
(NCT01385176)
Randomized
Double blind
NYHA functional
classes II and III
EF #35%
LVESD >5.5 cm
QRS interval <130 ms
96 1. LVESD (6 months)
2. NYHA functional class, VO2 max,
SF-36 and MLHFQ QoL scores,
pro-BNP
No sig change in LVESD
Signiﬁcant improvement in
NYHA functional class and
QoL scores
ANTHEM-HF
(NCT01823887)
Randomized
Open label
NYHA functional
classes II and III
EF #40%
QRS interval <150 ms
60 1. Change in EF and LVESV
(6 months)
2. NYHA functional class, 6MWD,
MLHFQ QoL scores, LVESD,
HRV, BNP
Signiﬁcant increase in EF
(4.5%); no change in LVESV
Signiﬁcant improvement in
NYHA functional class and
QoL score
INOVATE-HF
(NCT01303718)
Randomized
Open label
NYHA functional class III
EF #40%
LVESD 5–8 cm
730 1. Composite all-cause mortality/
HF hospitalizations (end of
study); freedom from
procedure-/system-related
complications (90 days); all-
cause death or complications
(12 months)
2. LVESV index, 6MWD, KCCQ QoL
scores, hospitalization-free
days
No signiﬁcant difference in
all-cause mortality and HF
hospitalizations; signiﬁcant
improvement in 6MWD,
KCCQ QoL; no safety issues
identiﬁed
6MWD ¼ 6-min walk distance; ANTHEM-HF ¼ Autonomic Regulation Therapy via Left or Right Cervical Vagus Nerve Stimulation in Patients With Chronic Heart Failure;
BNP ¼ B-type natriuretic peptide; CardioFit ¼ CardioFit for the Treatment of Heart Failure; EF ¼ ejection fraction; HF ¼ heart failure; HRV ¼ heart rate variability;
INOVATE-HF ¼ INcrease of VAgal TonE in Heart Failure; KCCQ ¼ Kansas City Cardiomyopathy Questionnaire; LVESD ¼ left ventricular end-systolic diameter; LVESV ¼ left
ventricular end-systolic volume; MLHFQ ¼Minnesota Living With Heart Failure Questionnaire; NECTAR-HF ¼ Neural Cardiac Therapy for Heart Failure; NYHA ¼ New York Heart
Association; QoL ¼ quality of life; SF-36 Short Form 36 Questionnaire; VO2 max ¼ maximum volume of oxygen consumed.
FIGURE 2 Schematic Demonstrating the Location and Stimulation Sites for Device-Based Neuromodulation Modality
(A) Vagus nerve stimulator placed in right subpectoral region with standard transvenous pacing/sensing lead placed in right ventricular (closed loop) and vagus nerve
stimulating lead (dotted white lines) tunneled to cervical vagus region. (B) Vagus nerve stimulator placed in right subpectoral region with vagus nerve stimulating lead
(dotted white line) tunneled to cervical vagus region (open loop). (C) The spinal cord stimulation (SCS) generator is implanted in abdomen or paraspinous region with
stimulation lead (blue line) placed in dorsal epidural space at thoracic level 4. (D) Baroreﬂex stimulation generator placed in right subpectoral region with bilateral
stimulation leads tunneled to the carotid baroreceptor region. Modiﬁed and adapted with permission from Lopshire and Zipes (14). BAT ¼ baroreceptor activation
therapy; SCS ¼ spinal cord stimulation; VNS ¼ vagus nerve stimulation.
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FIGURE 3 Results of the CardioFit System Pilot Trial
(A) Change in New York Heart Association (NYHA) classiﬁcation at 3 and 6 months after vagus nerve stimulation. (B) Change in left ventricular
end-systolic volume index at 3 and 6 months. Reproduced with permission from De Ferrari et al. (22).
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99Living with Heart Failure Questionnaire quality of life
score improved signiﬁcantly, as did the distance on
the 6-min walk test. An analysis (blinded) of the
2-dimensional echocardiograms showed that there
was a signiﬁcant reduction in LV end-systolic volume,
and a signiﬁcant increase in LVEF (from 22  7%
to 29  8%), whereas there was a nonsigniﬁcant
decrease in LV end-diastolic volume. A pre-speciﬁed
follow-up of a group of patients at 1 (n ¼ 23) and 2
years (n ¼ 19) showed that many of the beneﬁcial
effects of VNS were maintained.
The ANTHEM-HF (Autonomic Regulation Therapy
via Left or Right Cervical Vagus Nerve Stimulation in
Patients With Chronic Heart Failure) study (23)
enrolled 60 patients with NYHA functional classes II
and III HF, LVEF <40%, and QRS <150 ms. Patients
were randomized to either left or right cervical VNS
using a proprietary “open loop” VNS system
(Figure 2B) that did not incorporate a right ventricular
sensing lead. The stimulation amplitude of VNS was
uptitrated over a 10-week period, with an average
stimulation amplitude of 2.0  0.6 mA. The primary
efﬁcacy endpoint was the change in LV end-systolic
volume. The LVEF increased by 4.5% (p < 0.05) in
the pooled analysis of right and left VNS, whereas
there was a nonsigniﬁcant change in LV end-systolic
volume compared with baseline values. Overall, 77%
of patients improved by at least 1 NYHA functional
class at 6 months, with a signiﬁcant improvement in
the Minnesota Living with Heart Failure score.
Although there was a trend toward greater improve-
ment with right-sided VNS, these differences were
not signiﬁcant statistically (Figure 4).
The NECTAR-HF (Neural Cardiac Therapy for Heart
Failure) study enrolled 96 patients with NYHAfunctional classes II and III HF, LVEF <35%, a QRS
interval <130 ms, and LV end-diastolic diameter
>55 mm (24). All of the patients enrolled received a
device implant and were then randomized 2:1 to
active treatment or sham treatment for the ﬁrst 6
months, followed by active treatment for all patients
from 6 to 12 months. The device used in NECTAR-HF
was also an open loop system (Figure 2B), similar to
the one used in ANTHEM-HF, that employed a helical
bipolar electrode. The stimulation amplitude of VNS
was uptitrated and attained an average stimulation
amplitude of 1.42  0.8 mA, which was less than that
which was achieved in the CardioFit pilot trial or the
ANTHEM-HF trial. The primary efﬁcacy endpoint,
which was the change in LV end-systolic diameter at
6-month follow-up, was not signiﬁcantly different
(p ¼ 0.60) in the treatment and control groups.
Secondary endpoints, including LV end-diastolic
dimension, LV end-systolic volume, LVEF, peak V02,
and N-terminal pro–B-type natriuretic peptide
(NT-proBNP) were not different between groups.
However, there were statistically signiﬁcant impro-
vements in quality of life scores for the Minnesota
Living with Heart Failure Questionnaire and the
NYHA functional class in the group receiving treat-
ment. Interestingly, an assessment of blinding, which
was performed at 6 months revealed that 70% of
the patients assigned to active treatment correctly
guessed their randomization group, which was likely
secondary to side effects of VNS with this device.
The INOVATE-HF (Increase of Vagal Tone in Heart
Failure) was a pivotal phase III multicenter random-
ized clinical trial designed to assess the effects of VNS
using the CardioFit closed loop system (Figure 2A) in
patients with symptomatic HF despite OMT (25,26).
FIGURE 4 Primary Clinical Endpoint of the ANTHEM-HF Trial
Mean and 95% conﬁdence intervals of echocardiographic changes after 6 months of
autonomic regulation therapy (overall, left-side treatment, and right-side treatment).
Reproduced with permission from Premchand RK et al. (23). ANTHEM-HF ¼ Autonomic
Regulation Therapy via Left or Right Cervical Vagus Nerve Stimulation in Patients With
Chronic Heart Failure; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular
end-systolic volume; LVESD ¼ left ventricular end-systolic diameter.
FIGURE 5 Primary Efﬁcacy Endpoint of the INOVATE-HF Trial
There was no signiﬁcant difference in the primary composite
outcome of death from any cause or a worsening heart failure
event in the vagus nerve stimulation (VNS) treatment arm when
compared with the control group (hazard ratio: 1.14; 95%
conﬁdence interval: 0.86 to 1.53; p ¼ 0.37). Reproduced with
permission from Gold et al. (26). INOVATE-HF ¼ INcrease of
VAgal TonE in Heart Failure.
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class III symptoms, LVEF <40% and LV end-diastolic
size 50 to 80 mm were randomized 3:2 to either
active treatment with device implantation or no im-
plantation. One month after implantation, patients in
the treatment arm underwent multiple scheduled
visits over 4 weeks, during which time the stimula-
tion output was gradually increased with a goal of
achieving current of 3.5 to 5.5 mA. Importantly, the
stimulation protocol for INOVATE-HF differed
slightly from the protocol that was used in the Car-
dioFit pilot, in that the on time for stimulation was
5.1  0.8 s in INOVATE-HF and was 7.1  4.8 s in the
pilot trial. The primary endpoint of this study was a
composite of all-cause mortality or unplanned HF
hospitalizations. There were 2 coprimary safety end-
points: freedom from procedure and system-related
complication events at 90 days and number of pa-
tients with all-cause death or complications at 12
months. On December 15, 2015, INOVATE-HF was
stopped by the Steering Committee on the recom-
mendation of the independent Data and Safety
Monitoring Board after the second planned interim
analysis showed that the trial was unlikely to show a
statistically signiﬁcant beneﬁt in the treatment arm.
Patients were followed for up to 4.3 years with a
mean follow-up of 16 months. The primary efﬁcacy
outcome occurred in 30.3% in the VNS group
compared with 25.8% in the control group (hazard
ratio: 1.14; 95% conﬁdence interval: 0.86 to 1.53; p ¼
0.37) (Figure 5). Quality of life, NYHA functional classand 6-min walking distance were favorably affected
by VNS (p < 0.05 for all); however, the LV end-systolic
volume index was not different between groups
(p ¼ 0.36). The effects of treatment on 6 pre-speciﬁed
subgroups for the primary efﬁcacy composite
outcome showed that the only signiﬁcant treatment
by subgroup interaction was for sex with worse out-
comes with VNS among female subjects (p ¼ 0.03);
however, a multivariate analysis of the primary efﬁ-
cacy endpoint showed that sex was not an indepen-
dent predictor of outcome. No statistically signiﬁcant
differences in heart rates were observed between
control and VNS therapy arms. Of note, the mean
stimulation current in INOVATE-HF was 3.9  1.0 mA
at the 6-month follow-up visit, with 73% of patients
achieving the goal of $3.5 mA.
SPINAL CORD STIMULATION. Spinal cord stimula-
tion (SCS) has been used for over 40 years to treat
chronic intractable pain. The concept for SCS origi-
nated following the revolutionary gate theory for the
origin of pain, which raised the possibility of sup-
pressing pain by “closing the gate” by activation of
large diameter afferent ﬁbers (27). The beneﬁts of SCS
have been reported in patients with refractory angina
both due to end-stage coronary artery disease and
cardiac syndrome X (28). Interestingly, SCS fared
similarly to surgical and laser endomyocardial
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101revascularization in severe refractory angina, without
an increase in ischemic events, suggesting that the
improvement in this condition was more complex
than the suppression of the nociceptive input asso-
ciated with myocardial ischemia. SCS applied at the
C7 to C8 or T1 to T6 levels (Figure 2C) theoretically
exerts its effects through activation of ANS, with a
resultant overall increase in parasympathetic tone.
Pre-c l in i ca l s tud ies of SCS . In an animal model of
MI, preemptive SCS resulted in marked infarct size
reduction, which was attenuated by alpha- and beta-
receptor blockade, suggesting an SNS inhibition by
SCS (29). SCS also reduced the occurrence of ven-
tricular tachycardia (VT)/VF from 59% to 23% in a
canine model in which ventricular arrhythmias were
elicited by transient myocardial ischemia (30). In a
subsequent study (31), 28 dogs with HF induced by
anterior MI and rapid pacing were assigned for 5
weeks to no therapy, carvedilol or SCS (delivered at
T4/T5 region for 2 h, 3 a day). LVEF that had
declined to 18% after the induction of HF, recovered
to 28%, 34%, and 47%, respectively, in the control,
carvedilol, and SCS groups. Subsequent studies using
the same animal model showed that SCS was superior
to carvedilol þ ramipril. Olgin et al. (32) raised the
interesting possibility that SCS at the T1 to T2 level
enhanced parasympathetic activity based on the
observation that SCS resulted in a signiﬁcant increase
in sinus cycle length and the AH interval, which could
be abolished by bilateral vagal transection. Other pre-
clinical studies have shown that SCS results inTABLE 2 Spinal Cord Stimulation
Study Design Patient Characteristics N
SCS HEART
(NCT01362725)
Nonrandomized
Open label
NYHA functional
classes III and IV
EF 20% to 35%
17
DEFEAT-HF
(NCT01112579)
Randomized
Single blind
NYHA functional class III
EF #35%
LVESD 5.5–8 cm
QRS interval <120 ms
66
Methodist SCS
(NCT01124136)
Randomized
Double blind
NYHA functional
classes III and IV
EF #30%
9
TAME-HF
(NCT01820130)
Nonrandomized
Open label
NYHA functional class III
EF #40%
LVESD 5–8 cm
0
DEFEAT-HF ¼ Determining the Feasibility of Spinal Cord Neuromodulation for the Treat
left ventricular end-diastolic volume; Methodist SCS ¼ Neurostimulation of Spinal Nerv
Stimulation for Heart Failure; TAME-HF ¼ Trial of Autonomic Neuromodulation for Treareduced burden of VT/VF and greater improvements
in EF in MI animal models than in control subjects,
possibly via SNS inhibition and/or parasympathetic
nervous system stimulation (30,33,34).
Cl in ica l s tud ies of SCS . Based on pre-clinical
models, several clinical studies with SCS have been
conducted in patients with HF (Table 2). The SCS
HEART (Spinal Cord Stimulation for Heart Failure)
study (35) evaluated the safety and efﬁcacy of an
implanted a SCS device in 17 patients with NYHA
functional class III or ambulatory NYHA functional
class IV HF. The primary efﬁcacy endpoint was based
on a composite score of changes in NYHA functional
class, peak maximum O2 consumption, LV end-
systolic volume, and LVEF. Analysis at 6 months
showed that 73% of patients had improvement in $4
of 6 efﬁcacy parameters and that there were no re-
ported deaths or device-device interactions. As of the
18-month follow-up, 2 patients had died, 2 were
hospitalized for HF, and there were no device-device
interactions. Four patients with VT/VF before
receiving the SCS therapy continued with VT/VF,
requiring implantable cardioverter-deﬁbrillator
intervention.
The largest randomized clinical trial of SCS in HF,
the DEFEAT-HF (Determining the Feasibility of Spinal
Cord Neuromodulation for the Treatment of Chronic
Heart Failure) randomized controlled study was
completed recently (36). DEFEAT-HF enrolled 81 pa-
tients with NYHA functional class III HF and a mean
LVEF of 29  5%, with 66 successfully randomizedOutcomes Results
1. Safety and efﬁcacy (composite
of change in NYHA functional
class, VO2 max, LVESV, EF)
(6 months)
2. Long-term safety (24 months)
Signiﬁcant improvement in >4
of 6 efﬁcacy parameters,
without signiﬁcant adverse
events
No signiﬁcant long-term
complications
1. LVESV index (6 months)
2. VO2 max, pro-BNP
No signiﬁcant change in LVESV
index
No signiﬁcant change in VO2 max
or pro-BNP level
Safety (composite of worsening
HF, hospitalizations,
arrhythmia, device-device
interaction) and efﬁcacy
(change in EF, VO2 max, BNP,
QoL scores) (2 yrs)
No adverse events and no
interference with ICD
No signiﬁcant change in EF or
BNP
1. Change in LVEDV, NYHA
functional class, and 6MWD
(6 months)
2. Safety, QoL scores, VO2 max, LV
systolic and diastolic function
Withdrawn
ment of Chronic Heart Failure; ICD ¼ implantable cardioverter-deﬁbrillator; LVEDV ¼
es That Affect the Heart; SCS ¼ spinal cord stimulation; SCS HEART ¼ Spinal Cord
tment of Chronic Heart Failure; other abbreviations as in Table 1.
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102and implanted with the SCS device system. All of the
patients were implanted with a SCS device that con-
sisted of a single 8-electrode lead in the epidural
space. The electrode was connected to an SCS stim-
ulator, which was placed subcutaneously in the
lateral abdominal wall. Stimulation electrodes were
placed to encompass the T2 to T4 levels. Patients
were randomized 3:2 to SCS or OMT (control) for 6
months; after 6 months, the control patients were
crossed over to the active therapy arm and 12-month
data were collected in both randomization arms.
The stimulation in the treatment group was pro-
grammed on for 12 h a day, on the basis of individual
sleep/wake cycles, at a stimulation frequency of
50 Hz, 200 ms pulse duration, and output set at 90%
maximum tolerated voltage determined while sitting.
The primary study endpoint was a reduction in the LV
end-systolic volume index after 6 months of SCS
therapy in the treatment arm versus the control arm.
Secondary outcomes included change in peak O2
consumption and change in NT-proBNP at 6 months.
The results of the DEFEAT-HF trial show that,
compared with guideline-directed medical therapy
alone, thoracic (T2 to T4) SCS in patients with NYHA
functional class III HFrEF, did not lead to changes in
LV structural remodeling (LV end-systolic volume
index) at 6 months (Figure 6). Moreover, thoracic SCSFIGURE 6 Primary Efﬁcacy Endpoint of the DEFEAT-HF Trial
There was no signiﬁcant difference in the change in left
ventricular end-systolic volume index (LVESVi) over 6 months
between the spinal cord stimulation and control groups
(p ¼ 0.30). The bottom line of the box equals the 25th
percentile, the top line equals the 75th percentile and the line
within the box equals the median. The dots represent patient
values that exceed the 75th percentile. Reproduced with
permission from Zipes et al. (36). DEFEAT-HF ¼ Determining the
Feasibility of Spinal Cord Neuromodulation for the Treatment of
Chronic Systolic Heart Failure.did not lead to signiﬁcant improvements in peak VO2
nor circulating levels of NT-proBNP at 6 months.
There were no differences between the groups in
freedom from death or hospitalization for HF at
6 months, change on Minnesota Living with Heart
Failure Score, change in NYHA functional class or
change in 6-min walk distance. SCS appeared to be
safe and well tolerated in patients with NYHA func-
tional class III HF, which is consistent with the
observation in patients without HF.
BAROREFLEX ACTIVATION THERAPY. BAT was
initially developed for the treatment of resistant hy-
pertension. Electrical stimulation of the baroreceptor
ﬁbers located in the carotid sinus (Figure 2D), leads to
centrally mediated reduction of sympathetic outﬂow
and increased parasympathetic tone, resulting in
reduced systemic vascular resistance (37). BAT using
a proprietary ﬁrst-generation implantable carotid si-
nus stimulator (Rheos Baroreﬂex Hypertension
Therapy System,CVRx, Minneapolis, Minnesota) was
studied in patients with severe hypertension re-
fractory to medical therapy. Implantation of the de-
vice involves exposure of the carotid sinuses and
positioning of the electrodes on the carotid surface.
The leads are than tunneled subcutaneously and
connected to the stimulation device placed on the
chest. Data from the DEBUT (Device Based Therapy in
Hypertension) trial with BAT showed substantial re-
ductions in patients with refractory hypertension
(38). A second-generation Barostim neo system
(CVRx), consists of a single lead that requires less
dissection of the carotid artery for implantation and
has a battery life of 3 years.
Pre-c l in i ca l s tud ies of BAT. Several pre-clinical
studies in large animal HF models have shown that
monotherapy with BAT improves global LV systolic
and diastolic function and partially reverses LV
remodeling both globally and at cellular and molec-
ular levels. When evaluated in dogs using a coronary
artery microembolization model, BAT resulted in a
signiﬁcant decrease in LV end-diastolic pressure and
circulating plasma NE. BAT also normalized the
expression of cardiac beta1-adrenergic receptors,
beta-adrenergic receptor kinase, and reduced inter-
stitial ﬁbrosis and cardiac myocyte hypertrophy (39).
In a pacing-induced tachycardia model of HF, BAT
was shown to improve survival, although arterial
pressure, resting heart rate, and LV pressure were not
different over time in baroreﬂex-activated versus
control dogs (40).
Cl in i ca l s tud ies of BAT. The ﬁrst clinical experi-
ence with BAT in HF was a single-center, open-label
evaluation in patients (n ¼ 11) with NYHA functional
TABLE 3 Baroreﬂex Activation Therapy
Study Design
Patient
Characteristics N Outcomes Results
Rheos DHF (NCT00718939) Randomized
Double blind
EF >45%
Elevated BNP or
pro-BNP
6 1. LVMI; safety (occurrence of all
adverse events) (6 months)
2. Change in blood pressure, BNP
or pro-BNP, QoL scores
Pending
Barostim neo HF
(NCT01471860)
and Barostim HOPE4HF
(NCT01720160)
Randomized
Open label
NYHA functional
class III
EF #35%
146 1. Safety (system and procedure-
related adverse event)
2. Efﬁcacy (change in NYHA
functional class, QoL scores,
6MWD) (6 months)
No signiﬁcant adverse events
Signiﬁcant improvement in
6MWD, NYHA functional
class, QoL scores, pro-BNP
level
BeAT-HF (NCT02627196) Randomized
Open label
NYHA functional
class III
EF #35%
800 1. Cardiovascular mortality and HF
morbidity (5 yrs); MANCE
(6 months)
Pending (estimated 2021)
BeAT-HF ¼ Barostim Therapy for Heart Failure; DHF ¼ Rheos Diastolic Heart Failure Trial; HOPE4HF ¼ Barostim Hope for Heart Failure Study; LVMI ¼ left ventricle mass index;
MANCE ¼ major adverse neurological and cardiovascular events; other abbreviations as in Table 1.
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103class III HF and an LVEF <40% (41), wherein patients
were treated with BAT for 6 months (Table 3). This
study showed that there was a signiﬁcant and sus-
tained 30% reduction in SNS activity, as measured by
microneurography of the peroneal nerve, that was
accompanied by an overall improvement in NYHA
functional class, quality of life score, and 6-min hall
walk distance. Cardiac structure and function,
assessed by 3-dimensional echocardiography, also
improved. The rate of HF hospitalization was also
substantially decreased compared with the 12 months
before implantation of the BAT system. More
recently, the Barostim neo system was evaluated in
146 patients with NYHA functional class III HF and a
LVEF #35%, who were randomized to guideline-
directed medical therapy þ BAT (n ¼ 76) or to
guideline-directed medical therapy alone (n ¼ 70).
BAT is uptitrated over a series of follow-up visits,
with a focus on achieving therapeutic stimulation
without side effects, such as excessive reductions in
heart rate or blood pressure. When compared with
control subjects, patients assigned to BAT had an
improvement in the 6-min walk test, in a quality of
life scores, in NYHA functional class ranking, and in
NT-pro-BNP values at 6 months. There was a trend
toward a decrease in HF hospitalizations in BAT-
treated patients; however, there was no signiﬁcant
difference in LVEF or other echocardiographic pa-
rameters between the BAT and the control group.
Importantly, there was no difference between the
BAT and the control group with respect to major
adverse and neurological and cardiovascular events
(42). In a subsequent analysis of the same patients,
the most pronounced effect of BAT was observed in
patients not treated with cardiac resynchronization
patients, possibly because there is less sym-
pathovagal imbalance in this subgroup of HF patients
(43). Based on the positive results of these earliertrials, a large pivotal trial is planned: BeAT-HF (Bar-
ostim Therapy for Heart Failure; NCT02627196). The
trial will randomize 480 patients with NYHA func-
tional class III HF (LVEF #35%) in a 1:1 fashion to
receive OMT or OMT þ BAT. The primary outcome
measures for BeAT-HF will be the rate of cardiovas-
cular mortality and HF mortality at study completion
(efﬁcacy endpoint) and major adverse neurological
and cardiovascular events at 6 months (safety
endpoint).
NEUROMODULATION OF THE FAILING
HEART: LOST IN TRANSLATION?
The recent disappointing results of the DEFEAT-HF
and INOVATE-HF trials raise the important question
of whether device-based modulation of the ANS is a
viable therapeutic strategy for patients with HF. The
precise reason(s) why the pre-clinical and early clin-
ical studies that supported the concept of neuro-
modulation have failed to translate into clinically
meaningful endpoints in randomized clinical trials is
not known; however, it may relate, at least in part, to
the well-recognized problems associated with repli-
cating the results of open-label trials that lack a
proper randomized control group, or to the phenom-
enon of “regression to the mean” that plagues the
reproducibility of small clinical trials. These state-
ments notwithstanding, there are several issues that
are unique to device-based strategies designed to
modulate the ANS that warrant further discussion.
DOSE MATTERS. One of the consistent lessons
learned from pharmacologic trials in HF trials is that
choosing the proper dose is critical (44). Although
choosing the proper dose in HF trials remains as much
an art as a science, choosing the proper stimulation
parameters for devices to achieve clinically mean-
ingful modulation of the ANS is even more
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104challenging, in large measure because of the lack of
clear method for establishing the correct excitation
parameters and/or duty cycles. For example,
choosing the proper “dose” for VNS is critical, insofar
as the vagus nerve is composed of bundles of small
unmyelinated (C-ﬁbers) and larger myelinated
(A-ﬁbers and B-ﬁbers) nerves, whose activation
properties are distinctly different. Because large
diameter ﬁbers reach activation threshold at lower
stimulation intensities than smaller diameter ﬁbers
do, VNS results in the recruitment of A-ﬁbers at lower
stimulation thresholds and recruitment of B-ﬁbers at
higher thresholds and then ends with recruitment of
C-ﬁbers at higher stimulation thresholds (45). When
uptitrating the stimulus strength of the VNS devices
in the setting of clinical trials, the amplitude of the
stimulus current is often limited by patient symptoms
(e.g., cough, dysphonia) and/or untoward hemody-
namic effects (e.g., bradycardia, hypotension). Thus,
the populations of afferent and efferent vagus nerve
ﬁbers that are activated by VNS will vary depending
on the stimulus strength employed and may therefore
differ from patient to patient even though these pa-
tients are receiving the “same” treatment. Germane
to this discussion, it is important to recognize that the
stimulation amplitudes used for VNS in NECTAR-HF
(1.2 mA), ANTHEM-HF (2.0 mA), the CardioFit pilot
trial (4.2 mA), and INOVATE-HF (3.9 mA) were all
quite different. What is unclear from these studies is
that with the exception of the CardioFit pilot trial, in
which VNS resulted in a decrease in heart rate and
increased heart rate variability, it is unclear whether
the various VNS stimulation protocols used in clinical
trials were sufﬁcient to stimulate the vagus nerve
and/or inhibit the SNS. Beyond stimulus strength,
choosing the proper duty cycle is largely empiric and
is again selected to minimize the side effects of VNS.
Importantly, the duty cycle for VNS for the pivotal
INOVATE-HF trial, wherein there was no change in
heart rate, was different from the duty cycle used for
the CardioFit pilot trial, wherein therein there was a
decrease in heart rate. Whether this change in the
duty cycle was clinically important and/or explains
the disparate outcomes in these 2 trials is not known.
Choosing the proper site of stimulation, strength of
stimulation, and duty cycle for SCS is also challenging
from the standpoint of designing clinical trials.
Pertinent to this discussion, previous work in dogs
has shown that SCS delivered at the T4 level dem-
onstrates a greater antiarrhythmic effect (33),
whereas that at the T1 level is associated with a
heightened parasympathetic tone (32). In the SCS
HEART study (35), continuous SCS was performed at
the mid-line and left of the mid-line at T1 and T3levels, whereas intermittent SCS was conducted at
mid-line of T2 for T4 levels in the DEFEAT-HF trial
(36). The stimulators in the SCS Heart study were
programmed to deliver continuous therapy 24 h/day
at 50 Hz, whereas SCS in the DEFEAT-HF trial was for
12 h/day at 50 Hz and was based on individual sleep/
wake cycles. Whether the differences in clinical out-
comes in these 2 trials is attributable to the site of
stimulation, strength of stimulation, and duty cycle is
unknown. Moreover, similar to the problem with VNS
in the preceding discussed, it is unclear whether the
various protocols that were used in the SCS HEART
study and DEFEAT-HF trial were sufﬁcient to restore
the proper sympathovagal balance in patients with
HF. Viewed together, the observations with regard to
the difﬁculties with VNS and SCS suggest that there is
a critical need to be able to perform “dose” response
studies that will allow investigators to have a better
understanding of the types of stimulation protocols
that will be most efﬁcacious.
AFFERENT VERSUS EFFERENT STIMULATION. As
noted, VNS is accomplished by placing an electrode
cuff around the right or left cervical vagus, resulting
in stimulation of both efferent and afferent ﬁbers of
the vagus nerve. The device and stimulation pro-
tocols used in the NECTAR-HF and ANTHEM-HF trials
were designed to stimulate afferent vagus nerve ﬁ-
bers, whereas the device and stimulation protocol
uses in the CardioFit pilot trial and INOVATE-HF trial
were designed, in theory, to stimulate efferent vagus
nerve ﬁbers. From a conceptual standpoint, it may be
more advantageous to stimulate afferent vagus nerve
ﬁbers, insofar as stimulation of the afferent vagus
nerve ﬁbers has been shown experimentally to
decrease sympathetic efferent nerve ﬁber activity to
the heart (46), which is believed to be beneﬁcial based
on a wealth of experimental and clinical observations.
Moreover, the majority of the preganglionic vagal ﬁ-
bers terminate in small ganglia located on the poste-
rior surfaces of the atrium, whereas far fewer ganglia
reside in ventricular tissue, raising the question of
whether direct stimulation of efferent vagus nerve
ﬁbers is beneﬁcial. However, it bears emphasizing
that it is currently unknown whether stimulating
afferent vagus nerves, efferent vagus nerves, or a
combination of afferent and efferent vagus nerves is
more beneﬁcial in the setting of HF. Similar types of
difﬁcult questions can be raised about SCS, where
electrode placement can lead to inhibition of SNS
trafﬁcking to the heart and/or in increased para-
sympathetic tone in the heart. Thus, there are a
number of important questions about how to target
device-based autonomic modulatory strategies.
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105THE NEED TO IDENTIFY RELIABLE “PHYSIOLOGIC
BIOMARKERS” OF AUTONOMIC TONE. The results of
the DEFEAT-HF and INOVATE-HF trials raise a number
of important questions about how one might design
future device-based clinical trials of autonomic mod-
ulation in HF. Based on the foregoing discussion, there
is a need to identify physiological measurements that
will allow investigators in future trials to determine
the proper site of stimulation, the proper strength of
stimulation, and the proper duty cycle for
device-based therapies. Although there are no direct
physiological measurements that reﬂect the restora-
tion of normal sympathovagal tone in HF, there are a
number “physiological biomarkers” that reﬂect
excessive SNS activation in HF. Conceptually,
normalization of markers of excessive SNS activation
could be used as a surrogate for the restoration of
“normal” autonomic tone, assuming that one could
ascertain how much normalization was required. The
measurements of excessive SNS activation that have
been studied inHF include plasma or urinaryNE levels,
assessment of local tissue NE spillover, muscle sym-
pathetic nerve activity (MSNA), uptake of the iodine
123I-metaiodobenzylguanidine in the heart, baroreﬂex
sensitivity, and heart rate variability (2). Currently,
MSNA and iodine 123I-metaiodobenzylguanidine im-
aging are considered to be the most accurate direct
measurements of SNS activity in HF patients. As noted,
the early studies with BAT showed that there was a
sustained decrease inMSNA following BAT, suggesting
thatMSNAmight be used to assess the normalization of
autonomic tone in future studies.
CONCLUSIONS
HF progresses, at least in part, because of increased
activity of the SNS that is accompanied by concomi-
tant withdrawal of parasympathetic activity. Despite
the use of guideline-directed medical therapy, most
patients will ultimately develop worsening HF that isaccompanied by increased morbidity and mortality. In
the foregoing review, we have discussed the rationale
for neuromodulation of the failing heart, as well as
summarized the recent clinical experience with VNS,
BAT, and SCS. Although the pre-clinical studies and
early clinical studies with VNS and SCS appeared
promising, the larger clinical trials have been neutral
with respect to the primary clinical endpoints. The
pivotal trial with BAT should start enrolling patients
shortly, but it will not report results for several years.
Thus, for the short term, we will be left to question
whether neuromodulation is a viable therapeutic
strategy for treating patients with HF.
Although the tendency for investigators and in-
vestors is to walk away from therapeutic areas that do
not yield immediate positive results, particularly with
regard to cardiac devices that are invasive and hence
entail some procedural risk, it is instructive to recall
that cardiac resynchronization therapy, which is now
a class I indication in HF patients, took over 2 decades
to evolve from a concept in animal models to wide-
spread clinical application. Although the initial
results of the early large clinical trials with device-
based autonomic modulation of the failing heart
have been disappointing, given how little we
currently understand about how to modulate the ANS
in HF, these initial results are perhaps not at all sur-
prising. This statement notwithstanding, the progress
in this ﬁeld over the past 5 years has been astounding,
and it clear that we have now entered an exciting new
therapeutic era that may one day allow clinicians to
use both devices and drugs to restore the proper
sympathovagal balance in HF.
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